You may have severe problems or die from some forms of blood clots, such as clots that travel to the lungs or that cause heart attacks or strokes. Your risk of getting a blood clot may also be increased during treatment with PROMACTA if you have normal or low platelet counts. High platelet counts and higher risk for blood clots. Your risk of getting a blood clot is increased if your platelet count is too high during treatment with PROMACTA. If MDS worsens to become AML, you may die sooner from AML If you have MDS and receive PROMACTA, your MDS condition may worsen and become AML. PROMACTA is not for treatment of people with a precancerous condition called myelodysplastic syndromes (MDS). Worsening of a precancerous blood condition to a blood cancer called acute myelogenous leukemia (AML).PROMACTA may cause serious side effects, including: What are the possible side effects of PROMACTA? right upper stomach area (abdomen) pain.yellowing of the skin or the whites of the eyes (jaundice).Tell your health care provider right away if you have any of these signs and symptoms of liver problems: Your health care provider may stop your treatment with PROMACTA if you have changes in your liver function blood tests. Your health care provider will do blood tests to check your liver function before you start taking PROMACTA and during treatment. PROMACTA may increase your risk of liver problems that may be severe and possibly life-threatening. PROMACTA can cause serious side effects, including: What is the most important information I should know about PROMACTA? Important Safety Information for PROMACTA ® (eltrombopag) It is not known if PROMACTA is safe and effective in children with chronic HCV or previously treated SAA, in children younger than 1 year with ITP, or children younger than 2 years when used in combination with standard immunosuppressive therapy as the first treatment for SAA. PROMACTA is for treatment of certain people with low platelet counts caused by persistent or chronic ITP, chronic hepatitis C virus (HCV), or severe aplastic anemia (SAA), not for a precancerous condition called myelodysplastic syndromes (MDS) or low platelet counts caused by other conditions or diseases. PROMACTA is not used to make platelet counts normal. PROMACTA is a prescription medicine used to treat adults and children 1 year and older with low blood platelet counts due to persistent or chronic immune thrombocytopenia (ITP) when other medicines to treat your ITP or surgery to remove the spleen have not worked well enough. PROMACTA is used to try to raise platelet counts in order to lower your risk for bleeding. Approved Uses and Important Safety InformationĪpproved Uses for PROMACTA ® (eltrombopag)
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |